, Funding: This work was supported by the European Research Council (ERC) under the Europe Union's 204
, Horizon 2020 research and innovation program
, Government's Investissement d'Avenir program; Laboratoire d'Excellence, Integrative Biology, p.206
, Emerging Infectious Diseases
CRISPR-Cas immunity in prokaryotes, Nature, vol.526, pp.55-61, 2015. ,
Development and applications of CRISPR-Cas9 for genome 223 engineering, Cell, vol.157, pp.1262-78, 2014. ,
, Nat. News, vol.522, p.20, 2015.
, Pennisi E: The CRISPR craze, Science, vol.341, pp.833-839, 2013.
, , p.227
An updated evolutionary classification of CRISPR-Cas systems, Nat. 228 Rev. Microbiol, vol.13, pp.722-736, 2015. ,
, This study updated the classification and nomenclature of CRISPR-Cas systems and outlined their 230 occurrence and diversity in bacteria and archaea
Makarova 232 KS, Koonin EV, van der Oost J: Small CRISPR RNAs guide antiviral defense in prokaryotes, Science, vol.233, pp.960-964, 2008. ,
In 235 vitro reconstitution of Cascade-mediated CRISPR immunity in Streptococcus thermophilus, EMBO J, vol.236, pp.385-94, 2013. ,
, , p.238
The CRISPR/Cas bacterial immune system cleaves bacteriophage and 239 plasmid DNA, Nature, vol.468, pp.67-71, 2010. ,
Cas9-crRNA ribonucleoprotein complex 241 mediates specific DNA cleavage for adaptive immunity in bacteria, Proc. Natl. Acad. Sci, vol.242, pp.15539-15540, 2012. ,
A programmable dual244 RNA-guided DNA endonuclease in adaptive bacterial immunity, Science, vol.337, p.11, 2012. ,
, Applications of CRISPR technologies in research and beyond. Nat. 246 Biotechnol, vol.34, pp.933-941, 2016.
Sequence-specific antimicrobials using efficiently delivered 248 RNA-guided nucleases, Nat Biotechnol, vol.32, pp.1141-1146, 2014. ,
This report established a proof of concept that CRISPR-Cas9 systems can be delivered by phages to 250 target E. coli in vitro and in vivo ,
Programmable repression 252 and activation of bacterial gene expression using an engineered CRISPR-Cas system, Nucleic Acids 253 Res, vol.41, pp.7429-7437, 2013. ,
RNA-guided editing of bacterial genomes 255 using CRISPR-Cas systems, Nat Biotechnol, vol.31, pp.233-239, 2013. ,
Repurposing endogenous type I CRISPR-Cas systems 257 for programmable gene repression, Nucleic Acids Res, vol.43, pp.674-681, 2015. ,
Repurposing 259 CRISPR as an RNA-guided platform for sequence-specific control of gene expression, Cell, vol.260, pp.1173-83, 2013. ,
Sensitizing pathogens to antibiotics using the CRISPR-Cas 262 system, Drug Resist. Updat. Rev. Comment. Antimicrob. Anticancer Chemother, vol.30, p.18, 2017. ,
, , p.264
Diversity, activity, and evolution of CRISPR loci in Streptococcus 265 thermophilus, J Bacteriol, vol.190, pp.1401-1413, 2008. ,
Self-targeting by CRISPR: gene regulation or 267 autoimmunity?, Trends Genet, vol.26, pp.335-375, 2010. ,
, , p.269
Interference by clustered regularly interspaced short palindromic repeat 270 (CRISPR) RNA is governed by a seed sequence, Proc Natl Acad Sci U A, vol.108, pp.10098-103, 2011. ,
, , p.272
RNA-guided complex from a bacterial immune system 273 enhances target recognition through seed sequence interactions, Proc Natl Acad Sci U A, vol.274, pp.10092-10099, 2011. ,
DNA interrogation by the CRISPR 276 RNA-guided endonuclease Cas9, Nature, vol.507, p.23, 2014. ,
278 Strong bias in the bacterial CRISPR elements that confer immunity to phage, Nat. Commun, vol.4, p.32, 2013. ,
Targeted DNA degradation using a CRISPR device stably carried in the 307 host genome, Nat. Commun, vol.6, p.6989, 2015. ,
CRISPR interference can prevent natural 309 transformation and virulence acquisition during in vivo bacterial infection, Cell Host Microbe, vol.310, pp.177-186, 2012. ,
Structure and activity of 312 the Cas3 HD nuclease MJ0384, an effector enzyme of the CRISPR interference, EMBO J, vol.313, pp.4616-4627, 2011. ,
Cas3 is a single315 stranded DNA nuclease and ATP-dependent helicase in the CRISPR/Cas immune system, EMBO J, vol.316, pp.1335-1377, 2011. ,
Bacterial DNA repair: recent insights into the mechanism of RecBCD, p.318 ,
, Nat. Rev. Microbiol, vol.11, pp.9-13, 2013.
Consequences of Cas9 cleavage in the chromosome of Escherichia, Nucleic Acids Res, vol.44, pp.4243-4251, 2016. ,
URL : https://hal.archives-ouvertes.fr/pasteur-01967442
, This study investigated the outcomes of Cas9-based self-targeting in bacteria and established the 322 interplay between DNA damage and DNA repair
Genetically modified filamentous phage as bactericidal agents: a pilot 324 study, Lett. Appl. Microbiol, vol.37, pp.318-323, 2003. ,
326 Genetically engineered phage harbouring the lethal catabolite gene activator protein gene with an 327 inducer-independent promoter for biocontrol of Escherichia coli, FEMS Microbiol. Lett, vol.328, pp.67-71, 2009. ,
, , p.330
, Genetically Engineered Phage To Deliver Antimicrobial Agents to Bacteria: an Alternative Therapy 331 for Treatment of Bacterial Infections, Antimicrob. Agents Chemother, vol.47, p.41, 2003.
, Therapy of Experimental, vol.333
, Pseudomonas Infections with a Nonreplicating Genetically Modified Phage. Antimicrob. Agents 334 Chemother, vol.48, pp.3817-3822, 2004.
, , p.336
Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials, Nat 337 Biotechnol, vol.32, pp.1146-50, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01103559
This report established a proof of concept that CRISPR-Cas9 systems can be delivered by phages to 339 target S. aureus in vitro and in vivo ,
Temperate and lytic bacteriophages programmed to 341 sensitize and kill antibiotic-resistant bacteria, Proc. Natl. Acad. Sci, vol.112, pp.7267-7272, 2015. ,
This study provides novel strategies to re-sensitize bacteria to antibiotics using plasmid targeting 343 CRISPR-Cas systems ,
H-NS-mediated repression of CRISPR-based immunity in Escherichia coli 346 K12 can be relieved by the transcription activator LeuO, Mol. Microbiol, vol.77, p.45, 2010. ,
Bacteriophage resistance mechanisms, Nat Rev Microbiol, vol.348, pp.317-344, 2010. ,
, Bacteriophage Therapy. Antimicrob. Agents Chemother, vol.350, pp.649-659, 2001.
Engineering Modular Viral Scaffolds for Targeted Bacterial 352 Population Editing, Cell Syst, vol.1, pp.187-196, 2015. ,
Development of expanded host range phage 354 active on biofilms of multi-drug resistant Pseudomonas aeruginosa, vol.355, p.49, 2016. ,
Extending the Host Range of 357 Bacteriophage Particles for DNA Transduction, Mol. Cell, vol.66, p.50, 2017. ,
CRISPR-based screening of genomic island excision 359 events in bacteria, Proc. Natl. Acad. Sci, vol.112, pp.8076-8081, 2015. ,
, This report established that native CRISPR-Cas systems can be co-opted to select for rare deletion 361 events of expendable genetic islands
363 Inactivation of CRISPR-Cas systems by anti-CRISPR proteins in diverse bacterial species ,
, , vol.1, p.16085, 2016.